Navigation Links
FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418
Date:3/4/2009

BONITA SPRINGS, Fla., March 4 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, today announced that its Investigational New Drug (IND) application for the Company's geranylgeranyltransferase inhibitor (GGTI-2418) has been accepted by the U.S. Food and Drug Administration. This will allow the company to open a Phase I study evaluating the safety of GGTI-2418 during the first quarter of 2009. GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that induces apoptosis by downregulating several pivotal oncogenic and tumor survival pathways.

"We are excited to reach this important corporate milestone and to advance this novel, targeted compound into the clinic," stated Edmundo Muniz, M.D., Ph.D., President and Chief Executive Officer of Tigris. "We look forward to completing the Phase I study of GGTI-2418 in two top Phase I cancer research centers and to continuing our rapid development of this first-in-class agent. This is the first geranylgeranyltransferase inhibitor to move to clinical phase studies."

Tigris in-licensed the exclusive worldwide rights to GGTI-2418 from Yale University and the University of South Florida.

About GGTI-2418

GGTI-2418 is a synthetic peptidomimetic inhibitor of GGTase I that appears to induce apoptosis by downregulating several pivotal oncogenic and tumor survival pathways. GGTase I catalyzes the lipid posttranslational modification which is required for the function of Rho GTPases (frequently found aberrantly activated in human cancer). GGTase I inhibitors block Rho function in cancer cells and induce a G1 phase cell cycle arrest by a mechanism involving induction of the CDK inhibitors p21waf and p27kip, CDK2 and CDK4 inhibition and hypophoshorylation of the tumor suppressor Rb. GGTase I inhibitors also induce apoptosis by a mechanism involving downregulation o
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
2. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
3. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
4. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
5. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
6. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
7. FDA Accepts Immucors Response to Warning Letter
8. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
9. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
10. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
11. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...ia/--ShanghaiBiolaxyannouncedthe,ChineseStateFood&...gationalnewdrugapplication(IND)foritsoralinsulinpr...atdiabetes.ThisIND,approvalallowsBiolaxytoinitiate...ordercharacteristicofhighbloodglucoseandpoor,metab...emicro-and,macro-vasculardiseases,lossofvision,kid...
(Date:11/24/2009)...ently approved the Promega PowerPlex 16 HS System ...ting DNA records for the National DNA Index System...B) -- The FBI recently approved the Promega Power...rticipating in, or generating DNA records for, the...contains more than seven million profiles and has ...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/-HamiltonThorneLtd.(T...derofadvancedlasersystemsandinstrumentsforthestemc...operationalandfinancialresultsforthethirdquarteren...ewas$1.46millioncomparedwith$1.43millioninQ32008,-...centinQ3,2008,-Netlossreducedto$148,000comparedto$...
(Date:11/24/2009)...re-FirstCall/--ArenaPharmaceuticals,Inc.(Nasdaq: A...esentatthePiperJaffray21stAnnualHealthCareConferen...acificTime)attheNewYorkPalaceHotelinNewYorkCity.Ja...isscheduledtoprovideanoverviewofthecompany,includi..., Aliveaudiowebcastofthepresentationwillbeavailabl...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2
...ield MR Imaging Services to Unprecedented Number o...c Patients, MALVERN, Pa., Feb. 4 Johns Hopkins B...first facility in the United,States to install the...om,Siemens Medical Solutions (http://www.usa.siem...bining 3 Tesla (T) strength and sensitivity with a...
...if., Feb. 4 Cell,Genesys, Inc. (Nasdaq: CEGE ) t...man and chief executive officer of Cell Genesys, w...vestor Conference in New York, New,York, on Monday...io webcast of the presentation will be accessible ... Genesys website, http://www.cellgenesys.com . If ...
...ntocor, Inc. announced today,that the Biologics Li...),has been accepted for review by the U.S. Food an...dult patients with chronic moderate to severe plaq...al antibody with a novel,mechanism of action that ...nterleukin-23 (IL-23), naturally occurring protein...
Other Biology Technology:Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio 2Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio 3Cell Genesys to Present at the BIO CEO and Investor Conference 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 3
(Date:11/23/2009)...gton, D.C. The community-associated strain of the... resistant to most common antibioticsposes a far g...making its way into hospitals, according to a stud...seases . , The new threat is easily picked up i...s and has increased the overall burden of MRSA wit...
(Date:11/23/2009)...w study by the Wildlife Conservation Society says ...amp in the Republic of Congopart of the "mother lo...yearare becoming increasingly threatened by growin...ommends protection of the swamp forests adjacent t... after recent surveys confirmed that high densitie...
(Date:11/23/2009)...PAIGN, Ill. A new study provides "incontrovertibl...ba on the island of Sumatra about 73,000 years ago...s from the epicenter, researchers report. , The ...of ash into the atmosphere, leaving a crater (now ...ometers long and 35 kilometers wide. Ash from the ...
Breaking Biology News(10 mins):New study finds MRSA on the rise in hospital outpatients 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2New U K NICE Guidance Supports Use of Hologics Adiana 28R 29 Permanent Contraception System 58314 1New U K NICE Guidance Supports Use of Hologics Adiana 28R 29 Permanent Contraception System 58314 2New U K NICE Guidance Supports Use of Hologics Adiana 28R 29 Permanent Contraception System 58314 3New U K NICE Guidance Supports Use of Hologics Adiana 28R 29 Permanent Contraception System 58314 4Red Cross Lending a Hand to Flood Victims Unable to Go Home 58312 1Red Cross Lending a Hand to Flood Victims Unable to Go Home 58312 2Red Cross Lending a Hand to Flood Victims Unable to Go Home 58312 3Free Upcoming Program Scheduled to Help Remove Barriers To Early Cervical and Breast Cancer Diagnosis for Local Women 58310 1Free Upcoming Program Scheduled to Help Remove Barriers To Early Cervical and Breast Cancer Diagnosis for Local Women 58310 2Free Upcoming Program Scheduled to Help Remove Barriers To Early Cervical and Breast Cancer Diagnosis for Local Women 58310 3Free Upcoming Program Scheduled to Help Remove Barriers To Early Cervical and Breast Cancer Diagnosis for Local Women 58310 4
... techniques have brought us the resurgence of Amer...the rescue of prized lobster fisheries. So how can...such failures, from the catastrophic loss of Guate...er salmon kill in 2006" , In this week,s special ...f Sciences (online), Indiana University political ...
...r odious? Is there something in the chemistry of a...erceive its smell? Scientists at the Weizmann Inst...at Berkeley have now discovered that there is, ind...ure of a substance can help predict whether we wil...ght and hearing, for instance, our perceptions are...
...produce cheap, sustainable solar energy by imitati...nia Institute of Technology professor Nate Lewis a...chitecture of grass and photosynthesis to capture ... at how Dr. Lewis and his CalTech research team ar...inexpensive everyday products like house paint and...
Other Biology News:Why conservation efforts often fail 2Sweet smell 2
...te enterprise microarray informatics platform for ...nalysis. Buy Acuity once and use it forever withou...r Quality Acuity has all the analysis tools you n...ontrol statistics and normalization, all the way t...
...ndustry standard microarray image analysis softwar... analysis tools, visualizations, automation capabi...s included with every GenePix scanner, and it also... all types of arrays. A wide range of spot finding...
PerkinElmer Spectrum Beer's Law QUANT Quantitative Software, Floppy Disk from PerkinElmer
Human CALCA EIA (Enzyme immunoassay) Kit, Host: Rabbit ; Extraction-free from BACHEM
Biology Products: